Business
Issue of Equity, PDMR Shareholding and TVR
Issue of Equity, PDMR Shareholding and TVR.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 5486Y Evgen Pharma PLC 06 March 2017 \n\n \n\n\n\n\nFor immediate release\n\n\n6 March 2017\n\n\n\n\n \n \n \n \n \n \nEvgen Pharma plc \n(\"Evgen Pharma\" or \"the Company\")\n Issue of Equity, Director/PDMR Shareholding and Total Voting Rights\nEvgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that it has received notices to exercise options over 129,729 ordinary shares in the Company including a notice from David Howat, a Person Discharging Managerial Responsibility. \nThe options were granted under The Evgen Pharma plc Long Term Incentive Plan and have an exercise price of nil pence per share. Accordingly, the Company has issued and allotted 129,729 new ordinary shares of 0.25 pence each (\"New Ordinary Shares\"). The New Ordinary Shares rank pari passu with the Company's existing issued ordinary shares. Application has been made to admit the New Ordinary Shares to trading on AIM and dealings in these shares are expected to commence at 8.00 a.m. on 10 March 2017. \nThere are no shares held in treasury, therefore following the admission of the New Ordinary Shares the total number of voting rights in the Company will be 73,272,591. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest under the Disclosure and Transparency Rules.\n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nwww.evgen.com\n\n\nc/o +44 (0) 20 7466 5000\n \n\n\n\n\n \n\n\n \n\n\n\n\nBuchanan\nMark Court, Sophie Cowles, Stephanie Watson\n\n\n+44 (0) 20 7466 5000\n \n\n\n\n\n \n\n\n \n\n\n\n\nNorthland Capital Partners Limited\nMatthew Johnson, Gerry Beaney, Margarita Mitropoulou (Corporate Finance)\nJohn Howes and Rob Rees (Corporate Broking)\n\n\n+44 (0) 20 3861 6625\n\n\n\n\n\n\n\n\n\n \nNotes for editors:\nAbout Evgen Pharma plc\nEvgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a ...